Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:CAPR

Capricor Therapeutics Q3 2026 Earnings Date & Estimates

Capricor Therapeutics logo
$6.59 -0.29 (-4.22%)
Closing price 10/14/2026 04:00 PM Eastern
Extended Trading
$6.63 +0.04 (+0.61%)
As of 06:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Capricor Therapeutics is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Capricor Therapeutics in Q3 2026

Capricor Therapeutics is expected to post earnings of -$0.1278 per share on revenue of $41.71 million. In the same quarter a year earlier Capricor Therapeutics reported -$0.54 per share. Capricor Therapeutics last reported on August 13, 2026, posting -$0.70 per share and missing the -$0.5889 consensus estimate. Capricor Therapeutics has beaten the consensus EPS estimate in 1 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.1278
Expected Revenue
$41.71 million
Prior-Year EPS
-$0.54

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.70 (Missed by -$0.1111)
EPS Beat Rate
1 of last 8 quarters

Prepare for the Q3 2026 Call

Capricor Therapeutics Q3 2026 Earnings FAQ

Capricor Therapeutics (NASDAQ:CAPR) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Capricor Therapeutics' Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Capricor Therapeutics to post earnings of -$0.1278 per share for Q3 2026.

The consensus revenue estimate for Capricor Therapeutics is $41.71 million for Q3 2026.

Capricor Therapeutics Earnings Headlines

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript
October 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4952622-capricor-therapeutics-inc-capr-discusses-hopeminus-3-open-label-extension-data-and-deramiocel
CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision
October 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/capr-stock-rises-nearly-5-233031877.html
Buffett's Final Warning: "The Dollar Is Going to Hell"
On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.tc pixel
October 15 at 1:00 AM  |  Decentralized Masters (Ad)
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Stock Now Rated "Hold" by Wall Street Analysts
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095323
Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data On Deramiocel For Upper Limb Function In Duchenne Muscular Dystrophy
October 5, 2026  |  marketscreener.comM
Capricor's Deramiocel Slows Upper Limb Decline In Duchenne Muscular Dystrophy
October 5, 2026  |  rttnews.comhttps://www.rttnews.com/3696568/capricor-s-deramiocel-slows-upper-limb-decline-in-duchenne-muscular-dystrophy.aspx
See More Capricor Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Capricor Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capricor Therapeutics and other key companies, straight to your email.

About Capricor Therapeutics

Capricor Therapeutics (NASDAQ:CAPR) is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research is based on technologies intended to modulate inflammation, fibrosis and tissue damage, with an emphasis on rare and degenerative conditions.

Capricor’s lead investigational product is deramiocel, formerly known as CAP-1002. It is an allogeneic cell therapy derived from cardiosphere-derived cells and is being developed for Duchenne muscular dystrophy, a progressive genetic disorder that causes muscle degeneration. The company has also developed an exosome technology platform for potential use in vaccines, therapeutics and drug delivery.

Founded in 2005 and headquartered in Beverly Hills, California, Capricor conducts its development activities primarily in the United States and works with research and industry partners as its programs advance. The company is led by Linda Marbán, Ph.D., who serves as president and chief executive officer and has been associated with the company since its formation.

View Capricor Therapeutics Profile
Earnings Tools